EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cronos Group's enterprise value is $-101.0 Mil.
Cronos Group's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-58.4 Mil. Therefore, Cronos Group's EV-to-EBITDA for today is 1.73.
The historical rank and industry rank for Cronos Group's EV-to-EBITDA or its related term are showing as below:
CRON'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -636.45 Med: -2.33 Max: 1777.29
Current: 2.27
During the past 10 years, the highest EV-to-EBITDA of Cronos Group was 1777.29. The lowest was -636.45. And the median was -2.33.
CRON's EV-to-EBITDA is ranked better than 94.57% of 718
companies
in the Drug Manufacturers industry
Industry Median: 14.21
vs CRON: 2.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Cronos Group EV-to-EBITDA Historical Data
The historical data trend for Cronos Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cronos Group's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cronos Group's EV-to-EBITDA falls into.
Cronos Group EV-to-EBITDA Calculation
Cronos Group's EV-to-EBITDA for today is calculated as:
Cronos Group's current Enterprise Value is $-101.0 Mil.
Cronos Group's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (NAS:CRON) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cronos Group's PE Ratio (TTM) for today is calculated as:
Cronos Group's share price for today is $1.93.
Cronos Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Cronos Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRON has been successfully added to your 